Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QAR3 | ISIN: US0044685008 | Ticker-Symbol: SP4P
Tradegate
05.06.25 | 20:46
3,150 Euro
-5,97 % -0,200
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ACHIEVE LIFE SCIENCES INC Chart 1 Jahr
5-Tage-Chart
ACHIEVE LIFE SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,0203,12005.06.
3,0503,11505.06.

Aktuelle News zur ACHIEVE LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.'It Takes A World' To Achieve Life-Saving Cures. Let's Not Penalize It5
21.05.Achieve Life Sciences to present new data demonstrating that cytisinicline reduced cravings and nicotine intake (POSITIVE)4
13.05.Achieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones5
ACHIEVE LIFE SCIENCES Aktie jetzt für 0€ handeln
13.05.Achieve Life Sciences Inc. Q1 Loss Increases In Line With Estimates3
13.05.ACHIEVE LIFE SCIENCES, INC. - 10-Q, Quarterly Report1
13.05.Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program187Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May...
► Artikel lesen
13.05.Achieve Life Sciences GAAP EPS of -$0.37 in-line1
13.05.ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report-
12.05.What to Expect from Achieve Life Sciences' Earnings1
12.05.Achieve Life Sciences Q1 2025 Earnings Preview2
21.04.Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine727ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission...
► Artikel lesen
21.03.Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory4
12.03.Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2024 Earnings Call Transcript3
11.03.Achieve Life Sciences GAAP EPS of -$0.36 misses by $0.033
11.03.ACHIEVE LIFE SCIENCES, INC. - 10-K, Annual Report3
11.03.Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program186Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British...
► Artikel lesen
11.03.ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report1
18.02.Here are Rogue Funds Updates on Achieve Life Sciences (ACHV)4
11.02.Achieve Life Sciences announces positive outcome of DSMC review for ORCA-OL cytisinicline clinical trial required for NDA submission (POSITIVE)9
10.02.ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report-
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1